{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:10:08Z","timestamp":1746403808769,"version":"3.40.4"},"reference-count":45,"publisher":"Europa Digital & Publishing","issue":"R","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.4244\/eijv9sra25","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T14:37:26Z","timestamp":1412260646000},"page":"R149-R154","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment"],"prefix":"10.4244","volume":"9","author":[{"given":"Yao-Jun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2774","reference":[{"key":"key-201473014052-0","doi-asserted-by":"publisher","first-page":"184S","DOI":"10.1378\/chest.114.3_Supplement.184S","article-title":"Primary pulmonary hypertension: insights into pathogenesis from epidemiology.","volume":"114","author":"Galie N.","year":"1998","journal-title":"Chest."},{"key":"key-201473014052-1","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1016\/S0300-8932(04)77159-6","article-title":"New insights on pulmonary arterial hypertension.","volume":"57","author":"Galie N.","year":"2004","journal-title":"Rev Esp Cardiol."},{"key":"key-201473014052-2","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension.","volume":"43","author":"Simonneau G.","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"key-201473014052-3","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).","volume":"30","author":"Galie N.","year":"2009","journal-title":"Eur Heart J."},{"key":"key-201473014052-4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension.","volume":"351","author":"Humbert M.","year":"2004","journal-title":"N Engl J Med."},{"key":"key-201473014052-5","first-page":"2416","article-title":"Developing new guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"30","year":"2009","journal-title":"Eur Heart J."},{"key":"key-201473014052-6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ahj.2007.03.001","article-title":"The value of approved therapies for pulmonary arterial hypertension.","volume":"153","author":"Rich S.","year":"2007","journal-title":"Am Heart J."},{"key":"key-201473014052-7","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1161\/CIRCULATIONAHA.108.782979","article-title":"The status of pulmonary arterial hypertension in 2008.","volume":"117","author":"Farber HW.","year":"2008","journal-title":"Circulation."},{"key":"key-201473014052-8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/CIRCULATIONAHA.106.674002","article-title":"Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.","volume":"118","author":"Ghofrani HA.","year":"2008","journal-title":"Circulation."},{"key":"key-201473014052-9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1378\/chest.77.4.525","article-title":"Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature.","volume":"77","author":"Juratsch CE.","year":"1980","journal-title":"Chest."},{"key":"key-201473014052-10","article-title":"Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo.","volume":"Epub AOP.","author":"Chen SL.","year":"2013 March 7.","journal-title":"EuroIntervention"},{"key":"key-201473014052-11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.","volume":"30","author":"Galie N.","year":"2009","journal-title":"Eur Heart J."},{"key":"key-201473014052-12","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1067\/mhj.2002.121806","article-title":"Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.","volume":"143","author":"Langleben D.","year":"2002","journal-title":"Am Heart J."},{"key":"key-201473014052-13","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.","volume":"39","author":"Galie N.","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"key-201473014052-14","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension.","volume":"41","author":"Barst RJ.","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"key-201473014052-15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10547-6","article-title":"Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades.","volume":"48","author":"Jones DA.","year":"1995","journal-title":"Mol Pharmacol."},{"key":"key-201473014052-16","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.","volume":"328","author":"Giaid A.","year":"1993","journal-title":"N Engl J Med."},{"key":"key-201473014052-17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease.","volume":"114","author":"Stewart DJ.","year":"1991","journal-title":"Ann Intern Med."},{"key":"key-201473014052-18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/pupt.1998.0129","article-title":"Effect of novel mixed ETA\/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries.","volume":"11","author":"MacLean MR.","year":"1998","journal-title":"Pulm Pharmacol Ther."},{"key":"key-201473014052-19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","article-title":"Effectiveness of a nonselective ET(A\/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.","volume":"103","author":"Jasmin JF.","year":"2001","journal-title":"Circulation."},{"key":"key-201473014052-20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3181\/00379727-231-2310840","article-title":"Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction.","volume":"231","author":"Sauvageau S.","year":"2006","journal-title":"Exp Biol Med (Maywood)."},{"key":"key-201473014052-21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000102534","article-title":"Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions.","volume":"44","author":"Sauvageau S.","year":"2007","journal-title":"J Vasc Res."},{"key":"key-201473014052-22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00005344-200408000-00007","article-title":"Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.","volume":"44","author":"Nishida M.","year":"2004","journal-title":"J Cardiovasc Pharmacol."},{"key":"key-201473014052-23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1183\/09031936.00078207","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension.","volume":"31","author":"Dupuis J.","year":"2008","journal-title":"Eur Respir J."},{"key":"key-201473014052-24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.","volume":"358","author":"Channick RN.","year":"2001","journal-title":"Lancet."},{"key":"key-201473014052-25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin LJ.","year":"2002","journal-title":"N Engl J Med."},{"key":"key-201473014052-26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.","volume":"24","author":"Humbert M.","year":"2004","journal-title":"Eur Respir J."},{"key":"key-201473014052-27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.","volume":"114","author":"Galie N.","year":"2006","journal-title":"Circulation."},{"key":"key-201473014052-28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.","volume":"371","author":"Galie N.","year":"2008","journal-title":"Lancet."},{"key":"key-201473014052-29","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.","volume":"117","author":"Galie N.","year":"2008","journal-title":"Circulation."},{"key":"key-201473014052-30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.","volume":"43","author":"Sastry BK.","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"key-201473014052-31","doi-asserted-by":"publisher","first-page":"851.e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.","volume":"151","author":"Singh TP.","year":"2006","journal-title":"Am Heart J."},{"key":"key-201473014052-32","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Galie N.","year":"2005","journal-title":"N Engl J Med."},{"key":"key-201473014052-33","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie N.","year":"2009","journal-title":"Circulation."},{"key":"key-201473014052-34","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","article-title":"The L-arginine-nitric oxide pathway.","volume":"329","author":"Moncada S.","year":"1993","journal-title":"N Engl J Med."},{"key":"key-201473014052-35","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie N.","year":"2009","journal-title":"Circulation."},{"key":"key-201473014052-36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1536\/ihj.52.233","article-title":"Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.","volume":"52","author":"Hatano M.","year":"2011","journal-title":"Int Heart J."},{"key":"key-201473014052-37","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.amjcard.2005.06.083","article-title":"Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.","volume":"96","author":"Gomberg-Maitland M.","year":"2005","journal-title":"Am J Cardiol."},{"key":"key-201473014052-38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":"Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.","volume":"134","author":"Benza RL.","year":"2008","journal-title":"Chest."},{"key":"key-201473014052-39","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.amjcard.2011.06.021","article-title":"Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension.","volume":"108","author":"Fox BD.","year":"2011","journal-title":"Am J Cardiol."},{"key":"key-201473014052-40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jjcc.2012.08.009","article-title":"Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.","volume":"60","author":"Yao A.","year":"2012","journal-title":"J Cardiol."},{"key":"key-201473014052-41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/13543784.2011.565048","article-title":"Riociguat for the treatment of pulmonary hypertension.","volume":"20","author":"Schermuly RT.","year":"2011","journal-title":"Expert Opin Investig Drugs."},{"key":"key-201473014052-42","doi-asserted-by":"publisher","first-page":"1023A","DOI":"10.1378\/chest.1462924","article-title":"Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1).","volume":"142(4_MeetingAbstracts)","author":"Ghofrani H.","year":"2012","journal-title":"CHEST Journal."},{"key":"key-201473014052-43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1378\/chest.68.6.807","article-title":"Acute pulmonary artery hypertension produced by distention of the main pulmonary artery in the conscious dog.","volume":"68","author":"Laks MM.","year":"1975","journal-title":"Chest."},{"key":"key-201473014052-44","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/01.CIR.0000140724.90898.D3","article-title":"Increased sympathetic nerve activity in pulmonary artery hypertension.","volume":"110","author":"Velez-Roa S.","year":"2004","journal-title":"Circulation."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:52:19Z","timestamp":1746402739000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/R_issue\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":45,"journal-issue":{"issue":"R","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["EIJV9SRA25"],"URL":"https:\/\/doi.org\/10.4244\/eijv9sra25","relation":{},"ISSN":["1774-024X"],"issn-type":[{"type":"print","value":"1774-024X"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}